AU2022366869A1 - Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof - Google Patents
Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof Download PDFInfo
- Publication number
- AU2022366869A1 AU2022366869A1 AU2022366869A AU2022366869A AU2022366869A1 AU 2022366869 A1 AU2022366869 A1 AU 2022366869A1 AU 2022366869 A AU2022366869 A AU 2022366869A AU 2022366869 A AU2022366869 A AU 2022366869A AU 2022366869 A1 AU2022366869 A1 AU 2022366869A1
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- cycloalkyl
- heteroalkyl
- optionally substituted
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163256057P | 2021-10-15 | 2021-10-15 | |
| US63/256,057 | 2021-10-15 | ||
| US202263390438P | 2022-07-19 | 2022-07-19 | |
| US63/390,438 | 2022-07-19 | ||
| PCT/US2022/046761 WO2023064586A1 (en) | 2021-10-15 | 2022-10-14 | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2022366869A1 true AU2022366869A1 (en) | 2024-05-02 |
Family
ID=84357982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2022366869A Pending AU2022366869A1 (en) | 2021-10-15 | 2022-10-14 | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240368139A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4416143A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024538128A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240148310A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022366869A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3234693A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL311999A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024004416A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023064586A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116602242B (zh) * | 2023-05-08 | 2024-01-23 | 中国水产科学研究院珠江水产研究所 | 一种提高反季鱼苗成活率的方法 |
| WO2025155882A1 (en) * | 2024-01-19 | 2025-07-24 | Icahn School Of Medicine At Mount Sinai | G9a/glp degradation / disruption compounds and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IL307931A (en) * | 2016-04-15 | 2023-12-01 | Epizyme Inc | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| MA47233A (fr) * | 2016-12-19 | 2019-10-23 | Epizyme Inc | Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation |
| AU2018243749A1 (en) * | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| WO2018195450A1 (en) * | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| AU2018353150B2 (en) * | 2017-10-18 | 2024-06-06 | Epizyme, Inc. | Methods of using EHMT2 inhibitors in treating or preventing blood disorders |
| US20210213014A1 (en) * | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
-
2022
- 2022-10-14 US US18/701,092 patent/US20240368139A1/en active Pending
- 2022-10-14 MX MX2024004416A patent/MX2024004416A/es unknown
- 2022-10-14 JP JP2024522501A patent/JP2024538128A/ja active Pending
- 2022-10-14 KR KR1020247016027A patent/KR20240148310A/ko active Pending
- 2022-10-14 IL IL311999A patent/IL311999A/en unknown
- 2022-10-14 CA CA3234693A patent/CA3234693A1/en active Pending
- 2022-10-14 WO PCT/US2022/046761 patent/WO2023064586A1/en not_active Ceased
- 2022-10-14 AU AU2022366869A patent/AU2022366869A1/en active Pending
- 2022-10-14 EP EP22802794.2A patent/EP4416143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023064586A1 (en) | 2023-04-20 |
| IL311999A (en) | 2024-06-01 |
| EP4416143A1 (en) | 2024-08-21 |
| US20240368139A1 (en) | 2024-11-07 |
| CA3234693A1 (en) | 2023-04-20 |
| MX2024004416A (es) | 2024-07-09 |
| JP2024538128A (ja) | 2024-10-18 |
| KR20240148310A (ko) | 2024-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3378859B1 (en) | Benzofuran derivative, preparation method thereof and use thereof in medicine | |
| KR102302830B1 (ko) | 1,3-벤조디옥솔 유도체 | |
| CN102762549B (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| CN121368593A (zh) | Kras抑制剂 | |
| CN112424188A (zh) | 作为parp7抑制剂的哒嗪酮 | |
| CN116209446B (zh) | 作为毒蕈碱性乙酰胆碱受体m4的正向别构调节剂的7-(哌啶-1-基)-4h-嘧啶并[1,2-b]哒嗪-4-酮衍生物 | |
| EP3681885B1 (en) | Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors | |
| AU2015238296B2 (en) | Substituted 4,5,6,7-tetrahydro-pyrazolo[1,5-a]pyrazine derivatives and 5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine derivatives as ROS1 inhibitors | |
| AU2016293444A1 (en) | Substituted tricyclics and method of use | |
| EP4055013B1 (en) | Wdr5 inhibitors and modulators | |
| BR112021011147A2 (pt) | Benzamidas de derivados de pirazolil-amino-pirimidinila e composições e métodos das mesmas | |
| CN103102342B (zh) | 氨基喹唑啉类衍生物及其盐和使用方法 | |
| KR102281550B1 (ko) | 아미노피리딘 유도체 및 이의 선택적 alk-2 억제제로서의 용도 | |
| EP4491228A2 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| KR20240112343A (ko) | 무스카린성 아세틸콜린 수용체 m4의 길항제 | |
| WO2023064586A1 (en) | Novel modulators of ehmt1 and ehmt2 and therapeutic use thereof | |
| CN113825757A (zh) | 取代的稠合双环类衍生物、其制备方法及其在医药上的应用 | |
| CN113518779A (zh) | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 | |
| CN112996783A (zh) | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| WO2020247679A1 (en) | Wdr5 inhibitors and modulators | |
| US20240262822A1 (en) | Wdr5 inhibitors and modulators | |
| CN118647610A (zh) | Ehmt1和ehmt2的新型调节剂及其治疗用途 | |
| WO2024216164A1 (en) | N2-((5-hydroxy)-2-pyridyl)-pyridine-2,4-diamine derivatives as ehmt1/2 modulators for the treatment of cancer | |
| HK40059624A (en) | Thienoheterocyclic derivative, preparation method therefor and medical use thereof | |
| HK40064826A (en) | Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines |